Scholarlink

<p>Rheumatoid arthritis (RA) is a severe autoimmune disease characterized by dysregulated functions of multiple immune cells such as phagocytes, lymphocytes, and dendritic cells. Bruton’s tyrosine kinase (BTK) and FMS-like tyrosine kinase 3 (FLT3) play critical roles in RA pathogenesis, regulating B-cell survival, myeloid cell differentiation, and dendritic cell activation. Starting from the lead compound CC-292, a series of novel 5-fluoro-aminopyrimidine derivatives were designed and synthesized as dual BTK/FLT3 inhibitors for potential RA therapy. Our in vitro screening revealed that compounds <b>7a</b>, <b>7b</b>, and <b>7c</b> are potent dual inhibitors, demonstrating potent activity with IC<sub>50</sub> values in the low nanomolar range. Among them, <b>7b</b> demonstrated particularly strong dual-target activity (BTK IC<sub>50</sub> = 18&#xa0;nM; FLT3 IC<sub>50</sub> = 10&#xa0;nM), along with high plasma stability and hepatic microsomal metabolic stability. In collagen-induced arthritis model, <b>7b</b> administration produced dose-dependent reductions in joint swelling and significantly mitigated cartilage degradation and bone erosion, as confirmed by histopathological evaluation. Acute toxicity tests revealed no obvious adverse effects at a dose of 1000&#xa0;mg/kg, indicating a promising safety profile. This work presents not only a promising lead compound but also a strategic framework for developing next-generation RA therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Discovery of 5-fluoro-aminopyrimidine derivatives as dual BTK/FLT3 inhibitors for the treatment of rheumatoid arthritis

  • 期刊论文

  • 发表日期：

    2026年2月18日

查看全文
  • Fansheng Ran,
  • Yifan Ma,
  • Tiantian Sun,
  • Liujie Ji,
  • Qinyan Cai,
  • Yanan Zhang,
  • Yong Ling,
  • Chunlin Zhuang

摘要

Rheumatoid arthritis (RA) is a severe autoimmune disease characterized by dysregulated functions of multiple immune cells such as phagocytes, lymphocytes, and dendritic cells. Bruton’s tyrosine kinase (BTK) and FMS-like tyrosine kinase 3 (FLT3) play critical roles in RA pathogenesis, regulating B-cell survival, myeloid cell differentiation, and dendritic cell activation. Starting from the lead compound CC-292, a series of novel 5-fluoro-aminopyrimidine derivatives were designed and synthesized as dual BTK/FLT3 inhibitors for potential RA therapy. Our in vitro screening revealed that compounds 7a, 7b, and 7c are potent dual inhibitors, demonstrating potent activity with IC50 values in the low nanomolar range. Among them, 7b demonstrated particularly strong dual-target activity (BTK IC50 = 18 nM; FLT3 IC50 = 10 nM), along with high plasma stability and hepatic microsomal metabolic stability. In collagen-induced arthritis model, 7b administration produced dose-dependent reductions in joint swelling and significantly mitigated cartilage degradation and bone erosion, as confirmed by histopathological evaluation. Acute toxicity tests revealed no obvious adverse effects at a dose of 1000 mg/kg, indicating a promising safety profile. This work presents not only a promising lead compound but also a strategic framework for developing next-generation RA therapies.